EUVIMEDEUVIMED entdecken
Crossref

Transamniotic Delivery of Surfactant Protein B mRNA in a Healthy Model

Kamila Moskowitzova, Abbie E Naus, Tanya T Dang, David Zurakowski, Dario O Fauza

Fetal Diagnosis and Therapy · 2024

DOI: 10.1159/000541429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fetal Diagnosis and Therapy, 2024. Verfasst von Kamila Moskowitzova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: RNA, Messenger, Pulmonary Surfactant-Associated Protein B, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We sought to determine whether exogenous surfactant protein B (SPB) mRNA could be incorporated and translated by the fetal lung after simple transamniotic administration.

Methods

Fetuses (n = 149) of twelve time-dated dams underwent intra-amniotic injections of either human SPB (hSPB) mRNA encapsulated into lipopolyplex (mRNA, n = 99) or lipopolyplex without mRNA (control; n = 50) on gestational day 17 (E17, term = E21–22). Lungs were screened for hSPB by enzyme-linked immunosorbent assay daily until term. Phosphatidylcholine (PC) (a surrogate for surfactant production) was measured in the amniotic fluid by fluorometric assay. Statistical analysis included nonparametric Wilcoxon rank sum test.

Results

Significantly improved survival in the mRNA group compared to controls was observed at E18 (100% vs. 85.7%) and E20 (100% vs. 83.3%) (both p < 0.001). When controlled by mRNA-free injections, hSPB protein was detected in the mRNA group’s lungs at E18, 19, and term (p = 0.002 to <0.001). Amniotic fluid PC levels were increased compared to control at term [285.9 (251.1, 363.9) μM versus 263.1 (222.8, 309.1) μM]; however, this did not reach significance (p = 0.33).

Conclusions

Encapsulated exogenous SPB mRNA can be incorporated and translated by fetal lung cells following intra-amniotic injection in a healthy rat model. Transamniotic mRNA delivery could become a novel strategy for perinatal surfactant protein replacement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, MessengerPulmonary Surfactant-Associated Protein BLungFemaleAnimalsPregnancyAmniotic FluidHumansRatsAmnionPhosphatidylcholines

Stichwörter der Autor:innen

Fetal mRNA therapySurfactant protein BSurfactant replacement therapiesTransamniotic mRNA therapyTransamniotic nucleic acid therapy

Substanzen

RNA, MessengerPulmonary Surfactant-Associated Protein BPhosphatidylcholines

Autor:innen und Institutionen

  • Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.

Zitieren

APA

Moskowitzova, K., Naus, A. E., Dang, T. T., Zurakowski, D., & Fauza, D. O. (2024). Transamniotic Delivery of Surfactant Protein B mRNA in a Healthy Model. Fetal Diagnosis and Therapy. https://doi.org/10.1159/000541429

Vancouver

Moskowitzova K, Naus AE, Dang TT, Zurakowski D, Fauza DO. Transamniotic Delivery of Surfactant Protein B mRNA in a Healthy Model. Fetal Diagnosis and Therapy. 2024. doi:10.1159/000541429

BibTeX
@article{Moskowitzova2024,
  author = {Moskowitzova, Kamila and Naus, Abbie E and Dang, Tanya T and Zurakowski, David and Fauza, Dario O},
  title = {Transamniotic Delivery of Surfactant Protein B mRNA in a Healthy Model},
  journal = {Fetal Diagnosis and Therapy},
  year = {2024},
  doi = {10.1159/000541429}
}
Kostenlos starten →